New product for brow furrows launched in the US and the UK
This article was originally published in Scrip
Executive Summary
Medicis has launched Dysport (abobotulinumtoxinA) in the US for the treatment of glabellar lines. The drug, an acetylcholine release inhibitor and a neuromuscular blocking agent, achieved regulatory approval for this indication from both the US FDA and EU authorities earlier this year. The FDA also approved Dysport for cervical dystonia, and Ipsen will launch the product in the US later this year for this indication. The product has also been launched in the UK, as Azzalure, by Galderma, also for glabellar lines. In the UK, its wholesale price is £41 per 125 unit vial. The product has been marketed as Dysport in the UK by Ipsen since the 1990s for medical indications such as blepharospasm.